An indirect sandwich ELISA for the determination of agkisacutacin in human serum: Application to pharmacokinetic study in Chinese healthy volunteers

Journal of Pharmaceutical and Biomedical Analysis

Volumn 70, Issue , 2012, Pages 396-400

  Zhao, Ya Nan ^a,b   Dai, Xiang Rong ^c   Liu, Juan Juan ^c   Li, Xiang Hong ^b   Yang, Jing Jing ^b   Sun, Hua ^b   Wu, Ping ^b   Shen, Jie ^b   Lu, Jian Ping ^b   Xie, Hai Tang ^b   Liu, Xiao Quan ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b WANNAN MEDICAL COLLEGE   (China)

^c Zhaoke Pharmaceutical Co Ltd   (China)

Author keywords

Agkisacutacin; ELISA; Membrane glycoprotein Ib; Pharmacokinetics

Indexed keywords

AGKISACUTACIN; LECTIN; UNCLASSIFIED DRUG;

ACCURACY; ANTIGENICITY; AREA UNDER THE CURVE; ARTICLE; BLEEDING TIME; BLOOD CLOTTING; CHINESE; CONTROLLED STUDY; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG STABILITY; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN EXPERIMENT; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SIDE EFFECT; THERMOSTABILITY; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION STUDY; VOLUNTEER;

AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; COLD TEMPERATURE; CROTALID VENOMS; DRUG STABILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; LIMIT OF DETECTION; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PROTEIN BINDING; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84866248393     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.06.001     Document Type: Article

References (28)

1. Hantgan R.R., Hindriks G., Taylor R.G., Sixma J.J., de Groot P.G. Glycoprotein Ib, von Willebrand factor, and glycoprotein IIb:IIIa are all involved in platelet adhesion to fibrin in flowing whole blood. Blood 1990, 76:345-353.
2. Chen Z., Lou J., Zhu C., Schulten K. Flow-induced structural transition in the beta-switch region of glycoprotein Ib. Biophys. J. 2008, 95:1303-1313.
3. Zou X., Liu Y., Chen Z., Cardenas-Jiron G.I., Schulten K. Flow-induced beta-hairpin folding of the glycoprotein Ibalpha beta-switch. Biophys. J. 2010, 99:1182-1191.
4. Kumar R.A., Dong J.F., Thaggard J.A., Cruz M.A., Lopez J.A., McIntire L.V. Kinetics of GPIbalpha-vWF-A1 tether bond under flow: effect of GPIbalpha mutations on the association and dissociation rates. Biophys. J. 2003, 85:4099-4109.
5. Konstantinides S., Ware J., Marchese P., Almus-Jacobs F., Loskutoff D.J., Ruggeri Z.M. Distinct antithrombotic consequences of platelet glycoprotein Ibalpha and VI deficiency in a mouse model of arterial thrombosis. J. Thromb. Haemost. 2006, 4:2014-2021.
6. Goto S., Sakai H., Goto M., Ono M., Ikeda Y., Handa S., Ruggeri Z.M. Enhanced shear-induced platelet aggregation in acute myocardial infarction. Circulation 1999, 99:608-613.
7. Eto K., Isshiki T., Yamamoto H., Takeshita S., Ochiai M., Yokoyama N., Yoshimoto R., Ikeda Y., Sato T. AJvW-2, an anti-vWF monoclonal antibody, inhibits enhanced platelet aggregation induced by high shear stress in platelet-rich plasma from patients with acute coronary syndromes. Arterioscler. Thromb. Vasc. Biol. 1999, 19:877-882.
8. Nuyttens B.P., Thijs T., Deckmyn H., Broos K. Platelet adhesion to collagen. Thromb. Res. 2011, 127:S26-S29.
9. Angiolillo D.J., Guzman L.A., Bass T.A. Current antiplatelet therapies: benefits and limitations. Am. Heart J. 2008, 156:S3-S9.
10. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Alfonso F., Macaya C., Bass T.A., Costa M.A. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol. 2007, 49:1505-1516.
11. Krasopoulos G., Brister S.J., Beattie W.S., Buchanan M.R. Aspirin resistance and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008, 336:195-198.
12. Peng M., Lu W., Beviglia L., Niewiarowski S., Kirby E.P. Echicetin: a snake venom protein that inhibits binding of von Willebrand factor and alboaggregins to platelet glycoprotein Ib. Blood 1993, 81:2321-2328.
13. Taniuchi Y., Kawasaki T., Fujimura Y., Suzuki M., Titani K., Sakai Y., Kaku S., Hisamichi N., Satoh N., Takenaka T., et al. Flavocetin-A and -B, two high molecular mass glycoprotein Ib binding proteins with high affinity purified from Trimeresurus flavoviridis venom, inhibit platelet aggregation at high shear stress. Biochim. Biophys. Acta 1995, 1244:331-338.
14. Kawasaki T., Taniuchi Y., Hisamichi N., Fujimura Y., Suzuki M., Titani K., Sakai Y., Kaku S., Satoh N., Takenaka T., et al. Tokaracetin, a new platelet antagonist that binds to platelet glycoprotein ib and inhibits von Willebrand factor-dependent shear-induced platelet aggregation. Biochem. J. 1995, 308:947-953.
15. Fujimura Y., Ikeda Y., Miura S., Yoshida E., Shima H., Nishida S., Suzuki M., Titani K., Taniuchi Y., Kawasaki T. Isolation and characterization of jararaca GPIb-BP, a snake venom antagonist specific to platelet glycoprotein Ib. Thromb. Haemost. 1995, 74:743-750.
16. Zhong S.R., Jin Y., Wu J.B., Chen R.Q., Jia Y.H., Wang W.Y., Xiong Y.L., Zhang Y. Characterization and molecular cloning of dabocetin, a potent antiplatelet C-type lectin-like protein from Daboia russellii siamensis venom. Toxicon 2006, 47:104-112.
17. Xu G., Ulrichts H., Vauterin S., De Meyer S.F., Deckmyn H., Teng M., Niu L. How does agkicetin-C bind on platelet glycoprotein Ibalpha and achieve its platelet effects?. Toxicon 2005, 45:561-570.
18. Kageyama S., Yamamoto H., Nakazawa H., Matsushita J., Kouyama T., Gonsho A., Ikeda Y., Yoshimoto R. Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys. Arterioscler. Thromb. Vasc. Biol. 2002, 22:187-192.
19. Cheng X., Qian Y., Liu Q., Li B.X., Zhang M., Liu J. Purification, characterization, and cDNA cloning of a new fibrinogenolytic venom protein, Agkisacutacin, from Agkistrodon acutus venom. Biochem. Biophys. Res. Commun. 1999, 265:530-535.
20. Li W.F., Chen L., Li X.M., Liu J. A C-type lectin-like protein from Agkistrodon acutus venom binds to both platelet glycoprotein Ib and coagulation factor IX/factor X. Biochem. Biophys. Res. Commun. 2005, 332:904-912.
21. Su L.J., Xiao L., Zhan T., Chen L., Dong Y.Q., Fang L., Cheng L.S., Liu J. Preparation and identification of monoclonal antibodies against snake venom C-type lectin like protein Agkisacutacin. Chin. J. Cell. Mol. Immunol. 2007, 23:1031-1033.
22. U.S.Food and Drug Administration Guidelines on General Principles of Process Validation 2001, May.
23. Peletier L.A., Gabrielsson J. Dynamics of target-mediated drug disposition. Eur. J. Pharm. Sci. 2009, 38:445-464.
24. Mager D., Jusko W.J. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J. Pharmacokinet. Phamacodyn. 2001, 28:507-532.
25. Mager D., Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm. Res. 2005, 22:1589-1596.
26. Woo S., Krzyzanski W., Jusko W.J. Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J. Pharmacokinet. Phamacodyn. 2007, 34:849-868.
27. Coller B.S. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb. Haemost. 2001, 86:427-443.
28. Mager D.E., Mascelli M.A., Kleiman N.S., Fitzgerald D.J., Abernethy D.R. Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. J. Pharmacol. Exp. Ther. 2003, 307:969-976.